Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Solid Biosciences Inc    SLDB

SOLID BIOSCIENCES INC

(SLDB)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/16/2019 08/19/2019 08/20/2019 08/21/2019 08/22/2019 Date
8.81(c) 9.3(c) 9.32(c) 9.08(c) 8.74 Last
2 826 762 1 868 974 658 396 742 559 229 712 Volume
+43.25% +5.56% +0.22% -2.58% -3.74% Change
More quotes
Financials (USD)
Sales 2019 -
EBIT 2019 -115 M
Net income 2019 -113 M
Finance 2019 66,2 M
Yield 2019 -
Sales 2020 -
EBIT 2020 -127 M
Net income 2020 -106 M
Finance 2020 72,4 M
Yield 2020 -
P/E ratio 2019 -3,21x
P/E ratio 2020 -4,62x
EV / Sales2019 infx
EV / Sales2020 infx
Capitalization 418 M
More Financials
Company
Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD.... 
More about the company
Surperformance© ratings of Solid Biosciences Inc
Trading Rating : Investor Rating : -
More Ratings
Latest news on SOLID BIOSCIENCES INC
08/14SOLID BIOSCIENCES : Management's Discussion and Analysis of Financial Condition ..
AQ
08/14SOLID BIOSCIENCES INC. : Results of Operations and Financial Condition, Financia..
AQ
08/14Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides ..
GL
07/26SOLID BIOSCIENCES INC. : Entry into a Material Definitive Agreement, Unregistere..
AQ
07/26Solid Biosciences Announces $60 Million Private Placement with New and Existi..
GL
06/28Sarepta surges after Pfizer gene therapy data raises safety concerns
RE
06/14SOLID BIOSCIENCES INC. : Submission of Matters to a Vote of Security Holders (fo..
AQ
05/16SOLID BIOSCIENCES : Reports First Quarter 2019 Financial Results and Provides Bu..
AQ
05/13SOLID BIOSCIENCES : Management's Discussion and Analysis of Financial Condition ..
AQ
05/13SOLID BIOSCIENCES INC. : Results of Operations and Financial Condition, Financia..
AQ
More news
Sector news : Bio Therapeutic Drugs
06:28aGSK's long acting HIV injection gets boost from study
RE
08/15European Medicines Agency Reviews Arthritis Treatment by Gilead, Galapagos
DJ
08/12REGENERON PHARMACEUTICALS : Two Experimental Ebola Drugs Reduce Mortality Rate
DJ
08/08Sarepta says adverse event report for DMD gene therapy erroneously submitted
RE
08/08AGENUS : FDA Accepts AGEN2373 IND, Triggering $7.5 Million Milestone
DJ
More sector news : Bio Therapeutic Drugs
Chart SOLID BIOSCIENCES INC
Duration : Period :
Solid Biosciences Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SOLID BIOSCIENCES INC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 10,29  $
Last Close Price 9,08  $
Spread / Highest target 142%
Spread / Average Target 13,3%
Spread / Lowest Target -55,9%
EPS Revisions
Managers
NameTitle
Ilan Ganot President, Chief Executive Officer & Director
Andrey J. Zarur Chairman
Alvaro Amorrortu Chief Operating Officer
Jennifer Ziolkowski Chief Financial Officer & Treasurer
Carl Morris Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
SOLID BIOSCIENCES INC-66.12%418
GILEAD SCIENCES2.53%81 218
VERTEX PHARMACEUTICALS12.49%47 911
REGENERON PHARMACEUTICALS-20.27%32 584
GENMAB28.01%13 309
NEUROCRINE BIOSCIENCES, INC.37.73%9 007